Вакцинация против пневмококковой инфекции пациентов с системным ювенильным идиопатическим артритом, получающих биологическую терапию: обзор международного опыта

В обзоре обобщен международный опыт иммунизации против пневмококка пациентов с системным ювенильным идиопатическим артритом (сЮИА), получающих биологическую терапию. Показана высокая эффективность и безопасность пневмококковых вакцин у детей с сЮИА. Многочисленные исследования демонстрируют адекватный иммунный ответ после вакцинации, в том числе на фоне терапии генно-инженерными биологическими препаратами. Профилактика пневмококковой инфекции у больных сЮИА снижает риск развития осложненных форм пневмококковых заболеваний.

1. who.int [Internet]. Health topics: Pneumonia. Available from: https://www.who.int/en/news-room/fact-sheets/detail/pneumonia.

2. Медико-демографические показатели Российской Федерации в 2016 году. Стат. справочник. — М., 2017. — 254 c.

3. World Health Organization [Internet]. Measuring impact of streptococcus pneumoniae and haemophilus influenzae type b conjugate vaccination [cited 2017 August 12]. WHO; 2017. Available from: http://www.who.int/tb/publications/global_report/en/.

4. cdc.gov [Internet]. Pneumococcal disease. Surveillance and reporting. Available from: https://www.cdc.gov/pneumococcal/surveillance.html.

5. Kasper DL, Fauci АS, Hauser SL, et al. Harrison’s manual of medicine. Harrison’s principles of internal medicine 19th ed. New York: McGraw Hill Education Medical; 2016.

6. Баранов А.А., Намазова-Баранова Л.С., Брико Н.И., и др. Вакцинопрофилактика пневмококковой инфекции у детей // Педиатрическая фармакология. — 2018. — Т. 15. — № 3. — С. 200–211. doi: 10.15690/pf.v15i3.1899.

7. O’Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–902. doi: 10.1016/S0140-6736(09)61204-6.

8. Schrag SJ, Beall B, Dowell S; World Health Organization. Communicable diseases cluster. Resistant pneumococcal infections: the burden of disease and challenges in monitoring and controlling antimicrobial resistance. WHO; 2001. Available from: http://www.who.int/iris/handle/10665/66846.

9. Rаkоczi Е, Szekanecz Z. Pneumococcal vaccination in autoimmune rheumatic diseases. RMD Open. 2017;3(2):e000484. doi: 10.1136/rmdopen-2017-000484.

10. Pinheiro FA, Souza DC, Sato EI. A study of multiple causes of death in rheumatoid arthritis. J Rheumatol. 2015;42(12): 2221–2228. doi: 10.3899/jrheum.150166.

11. Таточенко В.К., Озерецковский Н.А. Иммунопрофилактика-2018. Cправочник. 13-е изд., расш. — М.: Боргес; 2018. — 274 с.

12. Ventola CL. Immunization in the United States: recommendations, barriers, and measures to improve compliance: part 1: childhood vaccinations. PubFacts. 2016;41(7):426–436.

13. WHO/UNICEF. Ending preventable child deaths from pneumonia and diarrhoea by 2025. The integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD). 2013.

14. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41. doi: 10.1086/648593.

15. Steens A, Bergsaker MA, Aaberge IS, et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013;31(52):6232–6238. doi: 10.1016/j.vaccine.2013.10.032.

16. cdc.gov [Internet]. Pneumococcal disease — global pneumooccal disease and vaccine. Available from: https://www.cdc.gov/pneumococcal/global.html.

17. Ciruela P, Izquierdo C, Broner S, et al. The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage. Vaccine. 2018;36(50):7744–7752. doi: 10.1016/j.vaccine.2018.05.026.

18. Приказ Министерства здравоохранения РФ № 125н от 21 марта 2014 г. «Об утверждении национального календаря профилактических прививок и календаря профилактических прививок по эпидемическим показаниям», с изменениями и дополнениями от 16 июня 2016 г., 13 апреля 2017 г. Доступно по: http://base.garant.ru/191961/. Ссылка активна на 10.12.2018.

19. Брико Н.И., Цапкова Н.Н., Сухова В.А., и др. Эпидемиологическая оценка первых результатов национальной программы иммунизации детей раннего возраста против пневмококковой инфекции в России // Эпидемиология и вакцинопрофилактика. — 2017. — Т. 16. — № 5. — С. 16–21. doi: 10.31631/2073-3046-2017-16-5-16-21.

20. Филатов Н.Н., Костинов М.П., Елагина Т.Н., и др. Факторы, влияющие на охват вакцинацией против пневмококковой инфекции детей первого года жизни на начальных этапах вакцинации // Эпидемиология и вакцинопрофилактика. — 2017. — Т. 16. — № 3. — С. 78–83. doi: 10.31631/2073-3046-2017-16-3-78-83.

21. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309–318. doi: 10.1093/cid/cit816.

22. Баранов А.А., Намазова-Баранова Л.С., Таточенко В.К. Научное обоснование вакцинации детей с отклонениями в состоянии здоровья // Педиатрическая фармакология. — 2010. — Т. 7. — № 2. — С. 6–24.

23. Никитюк Н.Ф., Глущенко В.А., Панин И.В. Организация иммунопрофилактики лиц с нарушениями в состоянии здоровья // БИОпрепараты. Профилактика, диагностика, лечение. — 2016. — Т. 16. — № 1. — С. 35–42. doi: 10.30895/2221-996X-2016-16-1-35-42.

24. Davies HD; Committee on infectious diseases. Infectious complications with the use of biologic response modifiers in infants and children. Pediatrics. 2016;138(2). pii: e20161209. doi: 10.1542/peds.2016-1209.

25. Subesinghe S, Rutherford AI, Ibrahim F, et al. A large twocentre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK. BMC Musculoskelet Disord. 2016;17:322. doi: 10.1186/s12891-016-1187-4.

26. Симонова Е.Ю., Полевиченко Е.В. Характеристика внутрибольничного регистра детей с аспленией, проживающих в Ростовской области, и анализ охвата их вакцинацией против пневмококковой инфекции // Вестник Российского университета дружбы народов. Серия «Медицина». — 2010. — № 4. — С. 456–458.

27. Белов Б.С., Наумцева М.С., Тарасова Г.М. Вакцинация в ревматологии: эволюция взглядов на проблему // Медицинский совет. — 2017. — № 5. — С. 142–147. doi: 10.21518/2079-701X-2017-5-142-147.

28. Cassidy JT, Petty RE Laxer R, Lindsley C. Textbook of pediatric rheumatology. 6th Edition. Elsevier Science,2010. 800 р.

29. Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol. 2016;137(1):19–27. doi: 10.1016/j.jaci.2015.10.023.

30. Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015; 386(9990):258–265. doi: 10.1016/S0140-6736(14)61704-9.

31. Keyser FD. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev. 2011;7(1):77–87. doi: 10.2174/157339711794474620.

32. Maddur MS, Vani J, Lacroix-Desmazes S, et al. Autoimmunity as a predisposition for infectious diseases. PLoS Pathog. 2010; 6(11):e1001077. doi: 10.1371/journal.ppat.1001077.

33. Yokota S, Tanaka T, Kishimoto T. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculoskelet Dis. 2012;4(6):387–397. doi: 10.1177/1759720X12455960.

34. Farmaki E, Kanakoudi-Tsakalidou F, Spoulou V, et al. The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate vaccine in children with juvenile idiopathic arthritis. Vaccine. 2010;28(31):5109–5113. doi: 10.1016/j.vaccine.2010.03.080.

35. Kapetanovic MC, Nagel J, Nordstrom I, et al. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine. 2017;35(6):903–908. doi: 10.1016/j.vaccine.2016.12.068.

36. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392.

37. Юношеский артрит с системным началом. Клинические рекомендации [интернет]. — М.: Союз педиатров России; 2016. Доступно по: http://cr.rosminzdrav.ru/#!/recomend/58. Ссылка активна на 12.02.2019.

38. Гатторно М. Аутовоспалительные заболевания у детей // Вопросы современной педиатрии. — 2014. — Т. 13. — № 2. — С. 55–64. doi.org/10.15690/vsp.v13i2.973.

39. Bracaglia C, Prencipe G, De Benedetti F. Macrophage activation syndrome: different mechanisms leading to a one clinical syndrome. Pediatr Rheumatol Online J. 2017;15(1):5. doi: 10.1186/s12969-016-0130-4.

40. Machado SH, Xavier RM. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf. 2017;16(4): 493–500. doi: 10.1080/14740338.2017.1303479.

41. Roszkiewicz J, Orczyk K, Smolewska E. Tocilizumab in the treatment of systemic-onset juvenile idiopathic arthritis — singlecentre experience. Reumatologia. 2018;56(5):279–284.

42. Grevich S, Shenoi S. Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition. Adolesc Health Med Ther. 2017;8:125–135. doi: 10.2147/AHMT.S109495.

43. De Keyser F. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev. 2011;7(1):77–87. doi: 10.2174/157339711794474620.

44. Henrickson SE, Ruffner MA, Kwan M. Unintended immunological consequences of biologic therapy. Curr Allergy Asthma Rep. 2016;16(6):46. doi: 10.1007/s11882-016-0624-7.

45. Burke RA, White ND. Biologic disease-modifying antirheumatic drugs [Internet]. PSAP; 2014. Available from: https://www.accp.com/docs/bookstore/psap/p14b2_m1ch.pdf.

46. Horneff G. Biologic-associated infections in pediatric rheumatology. Curr Rheumatol Rep. 2015;17:66. doi: 10.1007/s11926-015-0542-z.

47. gene.com [Internet]. Medication Guide for tocilizumab. Available from: https://www.gene.com/download/pdf/actemra_prescribing.pdf.

48. Ogata A, Kato Y, Higa S, Yoshizaki K. IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review. Mod Rheumatol. 2019;29(2):258–267. doi: 10.1080/14397595.2018.1546357.

49. Moots RJ, Sebba A, Rigby W, et al. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. Rheumatology (Oxford). 2017;56(4):541–549. doi: 10.1093/rheumatology/kew370.

50. Kostik MM, Dubko MF, Masalova VV, et al. Identification of the best cutoff points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis. Semin Arthritis Rheum. 2015;44(4):417–422. doi: 10.1016/j.semarthrit.2014.09.004.

51. Jones G, Panova E. New insights and long-term safety of tocilizumab in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10(10):195–199. doi: 10.1177/1759720X18798462.

52. Lerkvaleekul B, Vilaiyuk S. Macrophage activation syndrome: early diagnosis is key. Open Access Rheumatol. 2018;10:117–128. doi: 10.2147/OARRR.S151013.

53. Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and metaanalysis of randomized controlled trials. Rheumatology (Oxford). 2011;50(3):552–562. doi: 10.1093/rheumatology/keq343.

54. Yun H, Xie F, Delzell E, et al. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare. Arthritis Rheumatol. 2016;68(1): 56–66. doi: 10.1002/art.39399.

55. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Modern Rheumatol. 2010;20(3):222–232. doi: 10.1007/s10165-010-0279-5.

56. Morel J, Constantin A, Baron G, et al. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French registry REGATE. Rheumatology (Oxford). 2017;56(10):1746–1754. doi: 10.1093/rheumatology/kex238.

57. Toplak N, Blazina S, Avcin T. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives. Drug Des Devel Ther. 2018;12:1633–1643. doi: 10.2147/DDDT.S114532.

58. Hoy SM. Canakinumab: a review of its use in the management of systemic juvenile idiopathic arthritis. BioDrugs. 2015;29:133. doi: 10.1007/s40259-015-0123-8.

59. Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthrit Rheumat. 2012;64:557–567. doi: 10.1002/art.33342.

60. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416–2425. doi: 10.1056/NEJMoa0810787.

61. Horneff G, Schulz AC, Klotsche J, et al. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther. 2017;19(1):256. doi: 10.1186/s13075-017-1462-2.

62. Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis. 2015;10:19. doi: 10.1186/s13023-015-0228-7.

63. Bhorat AE, Madhi SA, Laudat F, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIVinfected individuals naive to pneumococcal vaccination. AIDS. 2015;29:1345–1354. doi: 10.1097/QAD.0000000000000689.

64. Pasiarski M, Rolinski J, Grywalska E, et al. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients — preliminary report. PLoS One. 2014;9:e114966. doi: 10.1371/journal.pone.0114966.

65. Meroni PL, Zavaglia D, Girmenia C. Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying antirheumatic drugs. Clin Exp Rheumatol.2018;36(2):317–328.

66. Liang Y, Meng FY, Pan HF, Ye DQ. A literature review on the patients with autoimmune diseases following vaccination against infections. Hum Vaccin Immunother. 2015;11(9):2274–2280. doi: 10.1080/21645515.2015.1009337.

67. Nagel J, Geborek P, Saxne T, et al. The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients. Scand J Rheumatol. 2015;44(4):271–279. doi: 10.3109/03009742.2014.984754.

68. Nagel J. Pneumococcal vaccination in inflammatory rheumatic disease. Antibody response and protection against infections. Lund: Lund University, Faculty of Medicine; 2018.

69. Mori S, Ueki Y, Akeda Y, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis. 2013;72(8):1362–1366. doi: 10.1136/annrheumdis-2012-202658.

70. Tsuru T, Terao K, Murakami M, et al. Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. Mod Rheumatol. 2014;24(3):511–516. doi: 10.3109/14397595.2013.843743.

71. Bingham CO, Rizzo W, Kivitz A, et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 2014;74(5):818–822. doi: 10.1136/annrheumdis-2013-204427.

72. Jaeger VK, Hoffman HM, van der Poll T, et al. Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study. Rheumatology (Oxford). 2017;56(9):1484–1491. doi: 10.1093/rheumatology/kex185.

73. Jeyaratnam J, Ter Haar NM, Lachmann HJ, et al. The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey. Pediatr Rheumatol Online J. 2018;16(1):19. doi: 10.1186/s12969-018-0235-z.